FDA Approves Another Generic Mifepristone, Expanding Abortion Pill Access
The FDA has approved another generic version of mifepristone, the abortion pill, which is typically taken with misoprostol for two-thirds of U.S. abortions. This comes amidst ongoing restrictions in many states and criticism from anti-abortion groups.
Evita Solutions, a pharmaceutical company, received the green light from the FDA for its low-cost version of mifepristone. The drug is set to launch in January 2023, following a four-year wait for approval. The FDA's approval process for generic drugs is usually straightforward, with multiple copycat versions hitting the market after the original patent expires.
Mifepristone's access has been eased over time by the FDA, including allowing online prescribing and mail-order delivery in 2021. However, access remains restricted in many parts of the U.S. due to state laws banning abortion or imposing separate restrictions on the drug's use.
The approval of another generic mifepristone is expected to increase access to abortion pills, potentially challenging state-level restrictions. However, the drug's safety continues to be debated, with critics like Students for Life Action and Sen. Josh Hawley voicing concerns. Federal officials, including Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Marty Makary, have pledged to review mifepristone's safety.
